logo
Plus   Neg
Share
Email

NiSource Reaffirms FY19 Adj. EPS Outlook - Quick Facts

While reporting financial results for the third quarter on Wednesday, electric utility NiSource Inc. (NI) reaffirmed its adjusted net operating earnings guidance for the full-year 2019.

For fiscal 2019, company continues to project adjusted net operating earnings in the range of $1.27 to $1.33 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.31 per share for the year. Analysts' estimates typically exclude special items.

Further, the company now projects 2019 capital investments in a range of $1.7 billion to $1.8 billion, up from the prior guidance range of $1.6 billion to $1.7 billion.

Looking ahead to fiscal 2020, the company now expects adjusted net operating earnings in the range of $1.36 to $1.40 per share, capital investments in a range of $1.7 billion to $1.8 billion. The Street projects earnings of $1.38 per share for the year.

The company also expects to grow its adjusted earnings per share and dividend by 5 to 7 percent annually and make capital investments of $1.7 to $2.0 billion each year through 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT